Piper Jaffray Maintains Overweight on Hologic (HOLX)

Piper Jaffray is out with its report today on Hologic HOLX, reiterating Overweight. In a note to clients, Piper Jaffray writes, "With ~200 Tomo-ready systems seeded in the U.S., we believe there is ample room for upside to our forward expectations. Although management remains conservative in terms of the adoption curve, with a ~$50,000 existing investment in 2D Dimensions and a high margin $100,000-$150,000 software upgrade on the come, we believe the cycle could add as much as $0.07 to 2012 EPS (in addition to physician-office based upside). We highlight several scenario analyses on page two of this note. We reiterate our OW rating and $24 price target on HOLX shares." Shares of HOLX closed Thursday at $21.89.